HyperSight Technology

On September15,2025,the Radiation Oncology Centerat Jinshazhou Hospital of Guangzhou Universi- ty of Chinese Medicine successfully upgraded its Halcyon linear accelerator to version 4.0,making it the first device in China equipped with the advanced “HyperSight”image-guided technology.This milestone marks a significant advancement in the precision,speed,and safety of radiation therapy in China.The up- grade was jointly completed by Varian Medical Systems and the hospital,pioneering the introduction of cutting-edge international radiotherapy technology into domestic clinical practice.
Our Hospital’s First HyperSight Procedure:September 16,2025
Key Features of HyperSight Technology
This upgrade delivers a dual breakthrough in the Halcyon v4.0 system’s hardware and algorithms.En- hancements include faster ConeBeam CT positioning for superior IMRT accuracy,synergistically com- bined with the HyperSight imaging system-a technology setting a new benchmarkin precision radiother- apy through three key innovations.

Halcyon v4.0
Field-of-View(FOV) Expansion
The imaging area has been expanded from 43cm x 43cm to 86cm ×43cm. This larger coverage meets the demand for holisticimaging of complex anatomi- cal structures.
A Leap-Forward in lmage Quality
With clarity approaching diagnostic-level and simulation CT image quality, it can be directly used for target delineation and treatment plan dose optimiza- tion.
The Revolution inSpeed and Precision
The system reduces the conventionali CBCT scan time from 15 seconds tojust 6 seconds.This allows the scan to be completed within a single breath-hold,thereby eliminating respiratory motion artifacts.Furthermore,it enables real-time detection of anatomical changes during treat- ment.Upon identifying a shift,clinicians can immediately modify the target volume and recalcu- late the dose without the need to interrupt the session or perform a new simulation.This stream- lines the entire process and facilitates efficient dynamic adaptive radiotherapy.

+86 18928918121
发表回复